AstraZeneca Inks R&D Deal With Ramaswamy's Roivant for Hush-Hush Indication Post author:Sam Post published:October 18, 2017 Post category:BioPharma Vivek Ramaswamy’s parent company, Roivant Sciences, inked a development deal with Astra. Source: BioSpace You Might Also Like Novartis' Bet Pays Off as Advanced Accelerator Applications Wins FDA Nod for Lutathera January 25, 2018 Bay Area's Ardelyx Nabs $160M Deal With Kyowa Hakko Kirin November 27, 2017 AstraZeneca PLC Offloads Heart Drugs to Recordati in $300 Million Deal to Pump Up R&D May 21, 2017
Novartis' Bet Pays Off as Advanced Accelerator Applications Wins FDA Nod for Lutathera January 25, 2018
